Bioceres Crop Solutions Reports Fiscal Fourth Quarter and Full-Year 2025 Financial and Operational Results

Total revenues were $74.7 million in 4Q25 and $335.3 million in FY25

FY25 results reflect challenging year amid ag sector headwinds and macro pressures in Argentina

ROSARIO, Argentina--(BUSINESS WIRE)-- Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ: BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, announced financial results for the fiscal fourth quarter ended June 30, 2025. Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards. All comparisons in this announcement are year-over-year (YoY), unless otherwise noted.

Financial & Business Highlights

• Total revenues were $74.7 million in 4Q25 and $335.3 million in FY25, down 40% and 28% YoY respectively, reflecting weaker demand in Argentina and lower HB4-related sales.

• Gross profit was $25.2 million in 4Q25 and $131.7 million in FY25, down 47% and 29% YoY. While quarterly results showed some volatility, full-year gross margin remained stable at 39%, supported by higher-value proprietary products.

• Operating loss was $14.9 million for the quarter, net loss was $48.0 million and Adjusted EBITDA¹ was negative $4.5 million. For FY25, operating loss was $3.7 million, net loss was $55.2 million and Adjusted EBITDA¹ was $28.3 million.

• Net cash flow generated by operating activities reached $29.9 million in 4Q25, and $53.0 million in FY25, a 27% YoY increase from FY24, despite the decline in profitability, as the Company continued to prioritize efficiencies in working capital management and cash generation.

Management Review

Mr. Federico Trucco, Bioceres' Chief Executive Officer, commented: “We are reporting a disappointing final quarter to an extremely challenging fiscal year. Our results this quarter were significantly impacted by the shift in our seed business strategy, which alone accounted for close to half of the gross margin decline. While this impact was anticipated and carries positive implications for our business going forward, the persistent slowdown in Argentina and a higher-than-normal level of impairments also weighed on performance. We believe many of these effects are transitory and expect conditions to normalize in the coming months.

In response, we have accelerated adjustments to our cost structure, targeting operating expense savings of around 10-12%. We have also reduced our rate of incremental CAPEX and R&D investment by 50%, lowering it from nearly 6% of sales to between 2.5% and 3% for fiscal years 2026 and 2027. Importantly, we do not expect this slower pace of investment to affect near-term growth, as we already have the key registrations and manufacturing capacity in place to deliver on our three-year plan. At the same time, we will continue to adjust our working capital levels to better reflect our current business model and product mix, aiming to maintain them at approximately four to five months of sales.

Finally, we have taken steps to comply with our financial obligations and strengthen governance. We amended our note purchase agreements and outstanding notes, extending the convertible note maturities under new terms, and made related changes to our Board composition. As previously announced, we are also making changes to our leadership team to best support our financial and commercial priorities moving forward. With Enrique Lopez Lecube’s departure, we are searching for a new CFO, as well as re-engineering the CCO role.”

Key Financial Metrics

Table 1: 4Q25 & FY25 Key Financial Metrics
(In millions of U.S. dollars)	4Q24	4Q25	%CHANGE	FY24	FY25	%CHANGE
Revenue by Segment
Crop Protection	53.2	41.7	(22%)	227.2	181.9	(20%)
Seed and Integrated Products	33.3	8.4	(75%)	96.4	63.9	(34%)
Crop Nutrition	37.5	24.7	(34%)	141.2	89.5	(37%)
Total Revenue	124.0	74.7	(40%)	464.8	335.3	(28%)
Gross Profit	47.4	25.2	(47%)	186.6	131.7	(29%)
Gross Margin	38.3%	33.8%	(450 bps)	40.1%	39.3%	(86 bps)

	4Q24	4Q25	%CHANGE	FY24	FY25
GAAP Net income or loss	(1.0)	(48.0)	(4477%)	7.3	(55.2)	(857%)
Adjusted EBITDA1	19.9	(4.5)	(123%)	81.4	28.3	(65%)

4Q25 & FY25 Summary: Quarterly revenues were $74.7 million, a 40% year-over-year decline, reflecting weaker demand in Argentina across Crop Protection and Crop Nutrition, and a lower contribution from HB4-related sales. Despite the contraction in Argentina, international markets remained resilient, supported by bio-protection products and adjuvant sales. Gross profit was $25.2 million, down 47%, reflecting the same revenue dynamics. A less favorable product mix and temporary margin pressure in certain categories resulted in a gross margin contraction from 38% to 34%. Operating profit was negative $14.9 million, net loss was $48.0 million and Adjusted EBITDA¹ was negative $4.5 million.

For the full fiscal year, revenues totaled $335.3 million, down 28% from FY24. After a strong multi-year growth trajectory, FY25 was impacted by severe challenges in Argentina, one of the Company’s key markets, driven by: (i) extraordinary prior-year sales linked to peso devaluation, which led channels to accumulate inventories beyond short-term needs, (ii) weaker on-farm economics, and (iii) tightening financing across the agricultural sector. Revenues were also pressured in the Seeds segment, due to the transition of the HB4 business model. Gross profit for the year was $131.7 million, a 29% decline, reflecting lower sales across segments. Despite this contraction, gross margin remained broadly stable at 39%, supported by higher-value proprietary products where the company retained market share and achieved modest gains in other markets. Operating loss was $3.7 million, net loss was $55.2 million, and Adjusted EBITDA¹ was $28.3 million, mainly reflecting the sharp drop in gross profit.

The Company continued to prioritize working capital efficiencies and adapt its cost structure to current market conditions. Net cash flow from operating activities reached $29.9 million in 4Q25, up 28% year-over-year, and $53.0 million for the full year, up 27%. These results were achieved despite a significant year-over-year decline in profitability, underscoring the Company’s focus on cash discipline.

For a full version of Bioceres’ fourth quarter and full fiscal year 2025 earnings release, click here.

1 Please refer to the “Use of non IFRS financial information” section at this end of this document on our use of Adjusted EBITDA and its reconciliation to the most comparable IFRS financial measure.

Fiscal Fourth Quarter and Fiscal Year 2025 Earnings Conference Call

Management will host a conference call and question-and-answer session, which will be accompanied by a presentation available during the webcast or accessed via the investor relations section of the company’s website.

To access the call, please use the following information:

Date: Tuesday, September 9, 2025		Please dial in 5-10 minutes prior to the start time to register and join. The conference call will be broadcast live and available for replay here and via the investor relations section of the company’s website here.
Time: 8:30 a.m. EST, 5:30 a.m. PST
US Toll Free dial-in number: 1-833-470-1428		A replay of the call will be available through September 16, 2025, following the conference.
International dial-in numbers: Click here		Toll Free Replay Number: 1-866-813-9403
Conference ID: 832796		International Replay Number: Click here
Webcast: Click here		Replay ID: 962629

About Bioceres Crop Solutions Corp.

Bioceres Crop Solutions Corp. (NASDAQ: BIOX) is a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change. To do this, Bioceres’ solutions create economic incentives for farmers and other stakeholders to adopt environmentally friendlier production practices.

The company has a unique biotech platform with high-impact, patented technologies for seeds and microbial ag-inputs, as well as next generation Crop Nutrition and Protection solutions. Through its HB4® program, the company is bringing digital solutions to support growers’ decisions and provide end-to-end traceability for production outputs. For more information, visit here.

Forward-Looking Statements

This communication includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include estimated financial data, and any such forward-looking statements involve risks, assumptions and uncertainties. These forward-looking statements include, but are not limited to, whether (i) the health and safety measures implemented to safeguard employees and assure business continuity will be successful and (ii) we will be able to coordinate efforts to ramp up inventories. Such forward-looking statements are based on management’s reasonable current assumptions, expectations, plans and forecasts regarding the company’s current or future results and future business and economic conditions more generally. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, levels of activity, performance or achievement of the company to be materially different from any future results expressed or implied by such forward-looking statements, and there can be no assurance that actual results will not differ materially from management’s expectations or could affect the company’s ability to achieve its strategic goals, including the uncertainties relating to the other factors that are described in the sections entitled “Risk Factors” in the company's Securities and Exchange Commission filings updated from time to time. The preceding list is not intended to be an exhaustive list of all of our forward-looking statements. Therefore, you should not rely on any of these forward-looking statements as predictions of future events. All forward-looking statements contained in this release are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date they are or were made, and the company does not intend to update or otherwise revise the forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, except as required by law.

Unaudited Consolidated Statement of Comprehensive Income (Figures in million of U.S. dollars)
	Three-month period ended 06/30/2025	Three-month period ended 06/30/2024		Fiscal Year ended 06/30/2025	Fiscal Year ended 06/30/2024
Revenues from contracts with customers	74.4	124.3		333.3	464.8
Initial recognition and changes in the fair value of biological assets at the point of harvest	0.2	(0.3)		1.8	(0.0)
Cost of sales	(49.3)	(76.6)		(203.4)	(278.2)
Gross profit	25.2	47.4		131.7	186.6
% Gross profit	34%	38%		39%	40%
Operating expenses	(37.8)	(36.9)		(139.5)	(140.9)
Share of profit of JV	0.3	(0.4)		(0.9)	4.0
Change in net realizable value of agricultural products	(1.1)	(0.4)		(1.5)	(2.4)
Other income or expenses, net	(1.5)	0.7		6.6	(1.5)
Operating profit	(14.9)	10.5		(3.7)	45.9
Financial result	(26.2)	(15.6)		(50.1)	(34.8)
Profit/(loss) before income tax	(41.2)	(5.1)		(53.8)	11.1
Income tax	(6.8)	4.0		(1.3)	(3.8)
Profit/(loss) for the period	(48.0)	(1.0)		(55.2)	7.3
Other comprehensive loss	(0.0)	(0.5)		(0.7)	(0.8)
Total comprehensive profit/(loss)	(48.0)	(1.6)		(55.9)	6.5

Profit/(loss) for the period attributable to:
Equity holders of the parent	(44.3)	(0.5)		(51.8)	4.3
Non-controlling interests	(3.7)	(0.6)		(3.4)	3.0
	(48.0)	(1.0)		(55.2)	7.3
Total comprehensive profit/(loss) attributable to:
Equity holders of the parent	(44.2)	(0.9)		(52.4)	3.8
Non-controlling interests	(3.8)	(0.7)		(3.5)	2.7
	(48.0)	(1.6)		(55.9)	6.5

Weighted average number of shares
Basic	63.2	62.8		63.2	62.8
Diluted	63.2	63.5		63.2	63.5

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250909950981/en/

Bioceres Crop Solutions

Paula Savanti

Head of Investor Relations

investorrelations@biocerescrops.com

Source: Bioceres Crop Solutions Corp.